# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price tar...
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility wit...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price...
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in ...
Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...